Login or sign up
For business

Nodthera limited

3.9· 13 reviews
Average ratingAverage
3.9/ 5

Based on 13 reviews

531%
431%
338%
20%
10%
Jason Wieland
Reviews 1

I have been a loyal customer of Nodthera Limited for several years now and I must say that their services are truly outstanding. The quality of their products and the level of customer support they provide is second to none. The staff is always friendly and helpful, and they go above and beyond to ensure customer satisfaction. I highly recommend Nodthera Limited to anyone in need of their services. They are the best!

Henry Szczygielski
Reviews 1

I have been using Nodthera Limited's products for a while now and I have been consistently impressed with their quality. Their customer service is also excellent, always addressing any concerns or questions I have in a timely manner. I highly recommend them!

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Nodthera limited

NodThera is a biotechnology company treating chronic diseases by targeting inflammation at its source.

NodThera Limited: Revolutionizing Chronic Disease Treatment through Targeted Inflammation

NodThera is a biotechnology company that has been making waves in the medical industry for its innovative approach to treating chronic diseases. The company's mission is to target inflammation at its source, which is often the root cause of many chronic conditions such as arthritis, inflammatory bowel disease (IBD), and cardiovascular disease.

Founded in 2016 by a team of experienced scientists and entrepreneurs, NodThera has quickly established itself as a leader in the field of inflammation research. The company's cutting-edge technology platform allows it to identify and develop small molecule drugs that selectively target specific inflammasomes - protein complexes that play a key role in regulating the body's immune response.

NodThera's unique approach has already yielded promising results. In preclinical studies, the company's lead drug candidate NT-0167 demonstrated potent anti-inflammatory activity and was well-tolerated by test subjects. This drug is currently being evaluated for its potential to treat various inflammatory diseases.

One of NodThera's key strengths lies in its team of world-class scientists and researchers. Led by CEO Alan Watt, who previously served as Vice President at AstraZeneca, the company boasts an impressive roster of experts with extensive experience in drug discovery and development.

In addition to its talented team, NodThera also benefits from strong partnerships with leading academic institutions such as Oxford University and Imperial College London. These collaborations allow the company to tap into cutting-edge research and expertise while also providing opportunities for joint projects and knowledge-sharing.

Looking ahead, NodThera has ambitious plans for growth. The company recently secured $55 million in Series B funding from investors including Novo Holdings A/S, F-Prime Capital Partners, Sofinnova Partners, Sanofi Ventures, 5AM Ventures LLP., Johnson & Johnson Innovation – JJDC Inc., RTW Investments LP, and Cowen Healthcare Investments. This funding will be used to advance the development of NodThera's drug pipeline and expand its research capabilities.

Overall, NodThera is a company that is poised to make a significant impact on the field of chronic disease treatment. With its innovative approach, world-class team, and strong partnerships, the company is well-positioned to develop new therapies that could improve the lives of millions of people around the world.

Categories
Biotechnology